Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retapamulin versus sodium fusidate for impetigo
2004-004439-70Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in impetigo comparing Retapamulin arm with Sodium fusidate arm (2 arms). Primary endpoint: Clinical response at end of therapy. Started Feb 2005; status: completed.
02
Drugs
retapamulinfusidic acid
03
Conditions
impetigo
Beyond the preview
Go deeper on 2004-004439-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004439-70.